These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37241113)

  • 1. Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials.
    Dai JW; Wang CH; Chu CL; Liao SC
    Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241113
    [No Abstract]   [Full Text] [Related]  

  • 2. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
    J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of patients post reversal with idarucizumab.
    Raco V; Ahuja T; Green D
    J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
    Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
    Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan.
    Tsai LK; Lin HJ; Chua SK; Liao PC; Yang YP; Chou PC; Lee CW; Lin MJ; Chen HM; Yeh JT; Li YH
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):e27-e33. PubMed ID: 29122465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study.
    Levy JH; van Ryn J; Sellke FW; Reilly PA; Elsaesser A; Glund S; Kreuzer J; Weitz JI; Pollack CV
    Ann Surg; 2021 Sep; 274(3):e204-e211. PubMed ID: 31599808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of idarucizumab as antidote of dabigatran in daily clinical practice.
    van der Wall SJ; van Rein N; van den Bemt B; Kruip MJHA; Meijer K; Te Boome LCJ; Simmers TA; Alings AMW; Tieleman R; Klok FA; Huisman MV; Westerweel PE
    Europace; 2019 Mar; 21(3):414-420. PubMed ID: 30339226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes.
    van der Horst SFB; Martens ESL; den Exter PL; Bos MHA; van Mens TE; Huisman MV; Klok FA
    Thromb Res; 2023 Aug; 228():21-32. PubMed ID: 37267671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N; Morrill AM; Willett KC
    Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P
    Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
    Van der Wall SJ; Lopes RD; Aisenberg J; Reilly P; van Ryn J; Glund S; Elsaesser A; Klok FA; Pollack CV; Huisman MV
    Circulation; 2019 Feb; 139(6):748-756. PubMed ID: 30586692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
    Fang CW; Tsai YT; Chou PC; Chen HM; Lu CM; Tsao CR; Chen CL; Sun MC; Shih YS; Hsieh CY; Chen LA; Chen PL; Yeh JT; Li YH
    J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):815-820. PubMed ID: 30573284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
    Pollack CV; Reilly PA; Bernstein R; Dubiel R; Eikelboom J; Glund S; Huisman MV; Hylek E; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Sellke F; Stangier J; Steiner T; Wang B; Weitz JI
    Thromb Haemost; 2015 Jul; 114(1):198-205. PubMed ID: 26020620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world experience with reversal of dabigatran by idarucizumab.
    Haastrup SB; Hellfritzsch M; Nybo M; Hvas AM; Grove EL
    Thromb Res; 2021 Jan; 197():179-184. PubMed ID: 33227654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective Analysis of the Effectiveness of a Reduced Dose of Idarucizumab in Dabigatran Reversal.
    Stone L; Merriman E; Hanna M; Royle G; Chan H
    Thromb Haemost; 2022 Jul; 122(7):1096-1103. PubMed ID: 34814227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idarucizumab Reversal of Dabigatran in Patients with Acute Ischemic Stroke and Intracranial Hemorrhage: Comparison with Non-idarucizumab-Treated Patients.
    Frol S; Sernec LP; Hudnik LK; Šabovič M; Oblak JP
    CNS Drugs; 2021 Feb; 35(2):233-242. PubMed ID: 33548038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.
    Sheikh-Taha M
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):59-64. PubMed ID: 30203330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarucizumab for Dabigatran Reversal.
    Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
    N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases.
    Kermer P; Eschenfelder CC; Diener HC; Grond M; Abdalla Y; Abraham A; Althaus K; Becks G; Berrouschot J; Berthel J; Bode FJ; Burghaus L; Cangür H; Daffertshofer M; Edelbusch S; Eggers J; Gerlach R; Gröschel K; Große-Dresselhaus F; Günther A; Haase CG; Haensch CA; Harloff A; Heckmann JG; Held V; Hieber M; Kauert A; Kern R; Kerz T; Köhrmann M; Kraft P; Kühnlein P; Latta J; Leinisch E; Lenz A; Leithner C; Neumann-Haefelin T; Mäurer M; Müllges W; Nolte CH; Obermann M; Partowi S; Patzschke P; Poli S; Pulkowski U; Purrucker J; Rehfeldt T; Ringleb PA; Röther J; Rossi R; El-Sabassy H; Sauer O; Schackert G; Schäfer N; Schellinger PD; Schneider A; Schuppner R; Schwab S; Schwarte O; Seitz RJ; Senger S; Shah YP; Sindern E; Sparenberg P; Steiner T; Szabo K; Urbanek C; Sarnowksi BV; Weissenborn K; Wienecke P; Witt K; Wruck R; Wunderlich S
    Int J Stroke; 2020 Aug; 15(6):609-618. PubMed ID: 31955706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.